Peripheral Artery Disease Clinical Trial
— MAvERICOfficial title:
Motivating Physical Activity With Behavioural interVention and Electrical Stimulation Remotely in People With Intermittent Claudication (MAvERIC): a Feasibility Randomised Controlled Trial
Peripheral Arterial Disease (PAD) is a common vascular disease which commonly causes limb pain and reduced exercise tolerance termed Intermittent Claudication (IC). People with PAD and IC have impaired quality of life, reduced walking ability, and increased mortality compared to those who do not have the condition. Improving physical activity (PA) is important in individuals with IC it can improve function, morbidity and mortality rates. While supervised exercise classes are recommended by healthcare authorities they are geographically sparse, and not always accessible due to individuals walking limitations. While home-based exercise can be accessible and improve walking ability, it can be challenging for people with IC to initially plan, conduct, and stay motivated to complete a walking program unsupported, especially when they experience limb pain when walking. Investigators have shown that Transcutaneous Electrical Nerve Stimulation (TENS), a non-invasive pain management device, with aims to improve pain and walking distances in patients with IC may be an acceptable modality alongside advice and support from a physiotherapist to overcome these challenges. Investigators have also shown that motivational interviewing, education, and goal-setting with a physiotherapist (physical therapist) has the potential to increase PA, and quality of life. This study aims to conduct a feasibility trial of four telehealth physiotherapy sessions, alongside the provision of a CE-marked TENS device to reduce limb pain during physical activity. This will be compared to the usual care offered in NHS Lanarkshire
Status | Recruiting |
Enrollment | 48 |
Est. completion date | December 1, 2025 |
Est. primary completion date | July 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Clinical diagnosis of symptomatic Peripheral Arterial Disease (PAD) including resting ABPI <0.9 in at least one leg - Stable IC for =3 months - Walking limited primarily by claudication - Able to read and speak English to a level allowing satisfactory completion of the study procedures - Able to provide written informed consent for participation Exclusion Criteria: - Planned surgical or endovascular intervention for PAD within the next 3 months - Critical limb ischaemia - The presence of any absolute contraindications to exercise testing/training as defined by the American College of Sports Medicine (ACSM) - Previous experience of using TENS for PAD - Contraindications to TENS (including epilepsy, dermatological conditions, indwelling electrical pumps/pacemakers) and inability to apply TENS independently. - Patients who require walking aids including artificial limbs - Major surgery, myocardial infarction or stroke/ TIA in the previous 6 months - Co-morbidities that cause pain or limit walking to a greater extent than IC (e.g. severe arthritis, respiratory conditions) - Severe peripheral neuropathies above the ankle. - Participation in another research protocol |
Country | Name | City | State |
---|---|---|---|
United Kingdom | NHS Lanarkshire | Glasgow | Lanarkshire |
Lead Sponsor | Collaborator |
---|---|
Glasgow Caledonian University | King's College London, NHS Lanarkshire, St George's, University of London, University of Glasgow |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Evaluation and monitoring of intervention fidelity | This will be assessed by a member of the study team with reference to the MOSAIC materials and therapist training manual. | End of Study (12 weeks) | |
Primary | Recruitment rates | Measure recruitment rates (ratio of patients who consent to participate to potentially eligible patient recorded via the study screening log | End of Study (12 weeks) | |
Primary | Participant retention rate | Ratio of patients who completed the intervention and outcome assessment to the patient who consented | End of Study (12 weeks) | |
Primary | Adverse events | Record defined adverse events in all groups | End of Study (12 weeks) | |
Primary | Uptake of interventions | Measure uptake of intervention via log of TENS use and attendance at physiotherapy appointments and follow up phone calls | End of Study (12 weeks) | |
Primary | Qualitative analysis of participant experience of trial | Analysis of semi-structured discussions with participants regarding experience of trial and interventions | End of Study (12 weeks) | |
Primary | Theoretical framework of acceptability (TFA) questionnaire | Quantitative measurement of Acceptability of Intervention compared with usual care | End of Study (12 weeks) | |
Secondary | Change in daily physical activity | Total number of steps (activpal step counts) | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Change in daily physical activity | Upright and sitting events | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Change in daily physical activity | Walking events | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Change in daily physical activity | Event-based claudication index (ratio of walking events to upright events) participants undertake in a day | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Change in daily physical activity | Total duration of walking activity in minutes and seconds | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Patient Reported Outcome Measure | Disease specific quality of life will be as assessed using the Intermittent Claudication Questionnaire (ICQ). | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Patient Reported Outcome Measures | Generic quality of life via the EQ-5D-3L | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Patient Reported Outcome Measures | Pain quality will be recorded using the Short Form McGill Pain Questionnaire (MPQ) | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Patient Reported Outcome Measures | Average Pain intensity in the past 7 days will be recorded using a Visual Analogue Scale | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Patient Reported Outcome Measures | Pain self-efficacy via. the Pain Self-Efficacy (PSEQ) | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) | |
Secondary | Patient Reported Outcome Measures | Pain Catastrophizing via. the Pain Catastrophizing Scale (PCS) | Baseline, 6 weeks, 12 weeks, 6 months (follow up), and 12 months (follow up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05712395 -
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
|
N/A | |
Active, not recruiting |
NCT04534257 -
Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Completed |
NCT02554266 -
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
|
||
Completed |
NCT03921905 -
Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
|
||
Not yet recruiting |
NCT06369350 -
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion
|
Early Phase 1 | |
Recruiting |
NCT04545268 -
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
|
N/A | |
Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
Completed |
NCT02563535 -
Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT02522884 -
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular Systemâ„¢ in Femoropoliteal Arteries
|
N/A | |
Completed |
NCT02542267 -
In-Stent Restenosis Post-Approval Study
|
N/A | |
Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
Completed |
NCT02262949 -
A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System
|
N/A | |
Completed |
NCT02145065 -
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
|
N/A | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAMâ„¢ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Completed |
NCT01743872 -
Optical Imaging Measurement of Intravascular Solution Efficacy Trial
|
N/A | |
Recruiting |
NCT01424020 -
Walking Estimated Limitation Calculated by History - Study 2
|
Phase 4 | |
Active, not recruiting |
NCT01597453 -
NOR-SYS: The Norwegian Stroke in the Young Study
|
N/A |